AGTC-601 gene therapy shows efficacy and safety in model of FTD with granulin mutations
May 23, 2023
Researchers from Applied Genetic Technologies Corp. have reported preclinical data for AGTC-601, a novel AAVrh10-granulin (GRN) gene therapy being developed for the treatment of frontotemporal dementia (FTD) with GRN mutations.
